Introduction
A lot can go wrong in the development of a human brain. The staggeringly complex circuitry that constitutes the substrate of the mind requires an equally complex network of genes to orchestrate its self-assembly. Mutations a ecting any of a wide range of cellular processes can lead to altered neurodevelopment and result in neurological or psychiatric disease. In some cases, the e ects are quite specific, as in the link between mutations in genes controlling asymmetric cell division and microcephaly [ 1] , in genes a ecting the guidance of specific axonal tracts which lead to very distinctive neurological syndromes [2] or in genes controlling cell migration which underlie various cortical malformations [3] .
Many neurodevelopmental mutations, however, result in a di use and variable presentation of psychiatric or neurological symptoms, which by themselves are not sufficiently specific to recognise a distinct aetiology. Individual disorders are often diagnosed instead on the basis of additional characteristic phenotypes, such as typical facial morphology (e.g. Down syndrome or Williams syndrome), somatic markers (e.g. neurofibromatosis and tuberous sclerosis) or diagnostic magnetic resonance imaging findings (e.g. for cortical malformations). More and more commonly, however, karyotypic or molecular genetic tests, such as those for Fragile X or Rett syndrome, are being used to directly determine the underlying cause and diagnose patients with a specific genetic syndrome. Depending on one's definition of neurodevelopmental, there are hundreds to thousands of such Mendelian syndromes, each very rare.
The term neurodevelopmental disorder is also used to refer to disorders that are really quite common in the population, however, including schizophrenia (SZ, 1%), autism spectrum disorders (ASD, nearly 1%), epilepsy ( 0.85%) and mental retardation (or intellectual disability, 2%). After decades o rustration, the past couple of years have suddenly seen tremendous progress in unravelling the genetics of these disorders. This review will focus on these recent findings and their implications for the genetic architecture and pathogenic mechanisms of common neurodevelopmental disorders.
The genetic architecture of common neurodevelopmental disorders
Although research into epilepsy and mental retardation has mainly proceeded on the model of genetic heterogeneity and has been very successful in defining rare genetic syndromes, research into psychiatric disorders largely took a di erent route. Despite seminal findings of very rare mutations predisposing individually to SZ (e.g. DISC1 [ 4] ) or ASD (e.g. NLGNs [ 5] ), these fields largely turned to a common disease/common variant (CD/ CV) model where disease is thought to be caused by the inheritance in any individual of a combination of a large number of common variants. The reasons for the rejection of heterogeneous Mendelian inheritance in the case of SZ have been discussed elsewhere and can now be seen to have been based on unfounded assumptions ([ 6 ] , but see [7] for a conflicting analysis).
The CD/CV hypothesis was the foundation of genomewide association studies (GWAS), the idea being that if common variants predispose to illness, even only in combination with other alleles, this should be detectable as an increase in allele frequency in disease cases versus controls, i arge enough numbers are compared. Such studies have now been completed, with many thousands of subjects, and the primary conclusion is stark: there are no common variants that confer even a modest ( > 1.2-fold) statistical increase in risk of SZ [ 8, 9 , 10, 11] , ASD [12, 13] or epilepsy [ 14 ] .
On the other hand, a wealth o ndividual, rare mutations have recently been identified that predispose to ASD, SZ, epilepsy, mental retardation and other disorders. This has been made possible by the development of array-based technologies for comparative genomic hybridisation [15] that can detect deletions and duplications of chromosomal segments, or copy number variants (CNVs). Two seminal papers by Jonathan Sebat and colleagues found that CNVs, especially those a ecting genes involved in neurodevelopment, are enriched among patients with ASD [ 16] or SZ [ 17 ] . The realization that CNVs could also be detected through the analysis of genome-wide SNP data quickly led to the mining of GWAS datasets for this kind of mutation, providing additional support for the involvement of such mutations in common neurodevelopmental disorders [18,19,20 ,21,22] , including ADHD [ 23 ] , mental retardation [24 ,25 ] and epilepsy [26 ,27 ] .
These findings demonstrate that common disorders can be caused by rare and recent (often de novo ) mutations of large e ect, which are likely rapidly selected against [28 ] . CNVs of course are just the most readily detectable class of mutation and analyses in other Mendelian disorders show that they typically constitute only 10 15% of pathogenic mutations. Consistent with this, sequencing o ndividual genes has also revealed a large number of rare or private point mutations likely to be causal or strongly contributing to disease [29,30,31 ,32 ,33] . It should also be emphasized that while the association of de novoCNVs with disease implies dominant e ects, recessive causes of these disorders are also common they have, however, with some exceptions (e.g. [ 34 ] ), been less amenable to the discovery of specific loci.
Overlapping genetic aetiology
One of the surprises from this research has been the finding that many of the more common, recurrent CNVs and a number of single-gene mutations predispose not to one specific 'disorder' or diagnostic category, but to many [35,36 ,37 ,38] . This suggests a fundamental aetiological overlap between what have largely been defined clinically as distinct disorders. This conclusion is in agreement with the recognized fluidity of diagnoses in individual patients over time and is also supported by large-scale epidemiological studies which have shown individual and familial comorbidity between SZ, ASD, epilepsy, bipolar disorder, major depression, ADHD and other psychiatric diagnoses (e.g. [39, 40, 41 ] ). Thus, while an individual's risk of SZ is increased 10-fold if they have a sibling with SZ, their risk of bipolar disorder or autism or epilepsy is characterised by incomplete penetrance for particular disorders and variable expressivity.
From genotype to phenotype
The sources of phenotypic variability include both additional genetic and non-genetic factors. Non-genetic factors must play important roles in the ultimate expression of many phenotypes, as demonstrated by the fact that concordance rates for monozygotic twins for any of these disorders are substantially below one hundred percent. Phenotypic expression may be strongly a ected by various environmental factors, second 'hits', such as head injuries or febrile seizures in the development of epilepsy, psychosocial stressors or other experiential factors. However, there is also likely a crucial contribution from intrinsic, stochastic developmental variation, which is evident in normal development and increased when the system is perturbed by mutation. Distinct phenotypic states may thus result as the end-points of divergent developmental trajectories [42] .
Genetic context is also expected to have a large influence on the expression of phenotypes associated with a Figure 1 Genetic heterogeneity in neurodevelopmental disorders. Several types of mutation are shown. Mutation 1 is of high penetrance and predisposes strongly to a particular pro le of symptoms (e.g. trisomy 21). Such mutations will tend to arise de novo in sporadic cases, due to their serious e ects on reproductive tness. Mutation 2 is o ower penetrance and variable expressivity and its e ects are modi ed by the presence of additional variants in the genetic background. Mutation 2 could still be considered the primary causative mutation, in the sense that without it, the patient would not be expected to show psychiatric or neurological symptoms (e.g. DISC1 translocation). The modi er loci, which could include common variants (most obviously the Y chromosome), would not cause disease in the absence of some such primary mutation. In the third case, Mutation 2 and Mutation 3 are present in the same individual and show strong epistatic interactions. Either mutation may be capable of causing some set of symptoms alone but the combined e ect may be more severe or qualitatively di erent (e.g. multiple recurrent CNVs). This situation would lead to a more Table 1 Synaptic genes recently implicated in common neurodevelopmental disorders. Genes are included if their products are localized to the synapse, if mutations have been seen in multiple cases, either within or across disorders, or mutations have been seen in multiple members of a gene family or in genes encoded interacting proteins, and if the gene is not already associated with a de ned syndrome. Mutations in many additional genes with other functions are not included nor are CNVs where the e ect has not been localized to a speci c gene. ADHD, attention de cit hyperactivity disorder; ASD, autism spectrum disorder; BD, bipolar disorder; DD, developmental delay; E, epilepsy; MD, major depression; MR, mental retardation; OCD, obsessive compulsive disorder; SZ, schizophrenia; TS, Gilles de la Tourette's syndrome 18, 19, 21, 46, 57 ] a Not all supporting references could be included. particular mutation. It is certainly the norm for all phenotypes in animal models to show large modifying e ects of genetic background and epistatic interactions which can be complex and unpredictable [43 ] . Such e ects are also typical of even the most classically defined 'Mendelian' disorders, such as cystic fibrosis and retinitis pigmentosa [44] . Figure 1 illustrates a number of scenarios for how such genetic interactions may be manifested and how they will a ect patterns o amilial inheritance.
Segregation within families may often be imperfect, even in cases where there is strong statistical support from population studies that an individual recurrent mutation is associated with risk of a disorder. First, not all carriers of the mutation will have a particular disorder (this is expected under incomplete penetrance/variable expressivity). Second, and quite unexpectedly, the presumed pathogenic variant may be absent from some a ected individuals in the family [ 37 ,45 ,46,47] . This suggests that there are at least two independently segregating mutations in some families and raises the possibility that they may interact.
One recent study directly illustrates this kind of e ect. Evan Eichler and colleagues found numerous instances of a microdeletion at 16p12.1 in a large cohort of patients with developmental delay/intellectual disability with congenital malformation [48 ] . They also found a strong enrichment for the presence of some second-site CNV among 16p12.1-carriers in this cohort. Those individuals with a second 'hit' showed a more severe phenotype and in cases where the second CNV was associated with a known syndrome, these patients showed distinct phenotypic features. In cases where the 16p12. 
Convergence on neurodevelopmental pathways
Perhaps the most striking finding from recent genetic studies has been the convergence on genes involved in neurodevelopment [17 ,23 ,27 ,33,37 ,49 ,50,51] , particularly in aspects of synaptogenesis. A partial list of such 'synaptic' genes with mutations found in disease cases is given in Table 1 . These include a greater-thanexpected number of mutations a ecting multiple members of particular gene families (e.g. CNTN, CNTNAP, DLG, NLGN, SHANK, and SLITRK ), or genes whose protein products directly interact or perform related functions (NRXN1 NLGNs SHANKs ; DISC1 NDE1 ; NRG1 ERBB4 ). Deep sequencing of several of these genes in cases (including CNTNAP2 , DISC1 , SHANK2 and SHANK3 ) has identified additional point mutations, further strengthening the case for their pathogenicity [29,30,31 ,32 ] .
This is not to imply by any means that all the genes identified have roles in synaptic processes mutations in a huge number of other genes with diverse cellular functions can cause neurodevelopmental disease. Nor is altered synaptic development the only cause of pathogenic disruptions in neuronal networks epilepsy can, for example, also arise due to defects in ion channels or in cell migration during cortical or hippocampal morphogenesis. Nevertheless, disruptions in synaptic processes certainly seem to be one common route by which neurodevelopment can be compromised in a way that can lead to psychiatric disturbances.
We are now in the remarkable position of having gone, in the space o ust two or three years, from having identified only a handful o oci with causative mutations for these common conditions to a list that is too long to usefully publish in toto. Modelling these mutations in animals is beginning to provide insights into pathogenic mechanisms (e.g. [52,53 ,54 ] ) and to suggest points of phenotypic convergence across di erent mutations.
The future is now
The arrival of a ordable whole-genome sequencing now promises to reveal the full spectrum of mutations associated with these diseases and to further delineate the relevant molecular pathways. As well as a 'forward genetic' approach based on sequencing cases, it will be equally important to do 'reverse genetics' to define the range of possible phenotypes that can arise when gene X is mutated. This will be most readily achieved in family studies where all mutation-carriers can be identified and phenotyped, regardless of clinical status. Obtaining evidence that any particular mutation is causative will thus depend on careful phenotyping and the definition of what it is one thinks it is causing.
Many traditional diagnostic categories evidently represent umbrella terms for collections of genetically heterogenous syndromes, which will likely be increasingly defined by genetic lesion (e.g. [ 24 ,55 ] ). For clinical geneticists, knowledge of the genetic aetiology in each case may provide meaningful distinctions in genetic risk of great importance to individuals and their families. The ultimate hope is to use genetic discoveries to learn enough about the underlying neurobiology to generate novel and patient-specific therapeutic approaches for these common and devastating disorders. Following on from a seminal study in autism [ 16] , this was the first study to show that SZ is also associated with rare CNVs, especially enriched for those disrupting genes involved in neurodevelopment. It was quickly followed by a number of other studies confirming and extending these findings [18,19,20 ,21,22 ] . 27. Me ord HC, Muhle H, Ostertag P, von Spiczak S, Buysse K, Baker C, Franke A, Malafosse A, Genton P, Thomas P et al. : Genome wide copy number variation in epilepsy: novel susceptibility loci in idiopathic generalized and focal epilepsies . PLoS Genet 2010, 6:e1000962. Along with Ref. [ 26 ] , this study identifies CNVs in idiopathic epilepsy, demonstrating that it too is likely caused by rare mutations rather than polygenic e ects and implicating some of the same CNVs as seen in psychiatric disorders. 
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